Increased number of shares and votes in Medivir

Increased number of shares and votes in Medivir

The number of shares and the number of votes in Medivir have changed as
a result of the rights issue carried out by the company as well as the
exercise of employee stock options. 

Today, the last trading day of the month, there are in total 26,222,662
shares and 32,162,662 votes in Medivir.  

For additional information, please contact
Rein Piir, CFO & VP Investor Relations, Medivir;
Office phone +46 8 54683123
Cell phone +46 708 537 292.
 

Medivir
Based on its world class expertise in protease and polymerase inhibition
technology, Medivir develops drugs with primary focus on infectious
diseases. Its objective is to become a sustainable and profitable
specialty pharmaceutical company with a strong research base.  

Medivir's first pharmaceutical product - for the topical treatment of
cold sores - has recently been approved by the US FDA (trademark
"Xerese™") and in Europe (trademark "Xerclear™"). The product will be
commercialized through partners outside the Nordic region, where
Medivir intends to market and sell the product. 

For more information on Medivir, please see the company website:
www.medivir.se (http://www.medivir.se)